Abstract
Understanding the molecular changes that drive an acquired antiestrogen resistance phenotype is of major clinical relevance. Previous methodologies for addressing this question have taken a single gene/pathway approach and the resulting gains have been limited in terms of their clinical impact. Recent systems biology approaches allow for the integration of data from high throughput '-omics' technologies. We highlight recent advances in the field of antiestrogen resistance with a focus on transcriptomics, proteomics and methylomics.
Original language | English (US) |
---|---|
Pages (from-to) | e11-e17 |
Journal | Drug Discovery Today: Disease Mechanisms |
Volume | 9 |
Issue number | 1-2 |
DOIs | |
State | Published - Jun 2012 |
Externally published | Yes |
Bibliographical note
Funding Information:This work was supported in part by awards from the US Department of Health and Human Services to Robert Clarke: R01-CA131465 and U54-CA149147. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.